LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...

Leqembi's commercial performance is disappointing ... For the full-year, revenues amounted to $9.7bn, down 2% year-on-year, while GAAP diluted EPS was up 40%, to $11.18, and non-GAAP EPS $16. ...

0000875045false00008750452025-02-122025-02-12UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K CURRENT REPORTPursuant to Section 13 OR 15(d) of The Securities Exchange ...

LEQEMBI will come on and talk about it in some ... Fourth quarter non-GAAP diluted EPS was $3.44 and that's 17% higher than the fourth quarter of 2023. For the full year of 2024, total revenue ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as part of its ongoing evaluation of Leqembi (lecanemab), which was turned ...

While Leqembi sales performed well outside the U.S. and Skyclarys is set to grow internationally, Medicare Part D changes will hit its U.S. sales, reducing revenue by about $15–$30 million.

For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on ...

The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment. Leqembi is the result of ...